Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07067788 · ClinicalTrials.gov registry record

B.Brilliant Revelation Comparision Study

A clinical trial of Breast Cancer Screening, sponsored by University of Pennsylvania.

Recruiting
Registry status
100
Enrollment target
1
Study location

NCT07067788 is a study of Breast Cancer Screening that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 100 participants, below the 63,430-participant average among 8 other Breast Cancer Screening trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07067788, a study of Breast Cancer Screening, is actively recruiting participants, sponsored by University of Pennsylvania.

RECRUITING
Registry status
100 participants
Enrollment target
1
Study location

Study Summary

This is an observational study to evaluate the MAMMOMAT B.brilliant system. All diagnostic decisions are made by the treating radiologist based upon standard of care clinical imaging acquired on FDA approved devices

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST Breast Imaging

Study Locations (1)

Pennsylvania

  • Pennsylvania Hospital, Center for Breast Imaging - Philadelphia

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-12-15
Est. Completion 2027-01-30

Sponsor

University of Pennsylvania

1,423 total trials

What the Registry Record Tells You About NCT07067788

The ClinicalTrials.gov registry entry for NCT07067788 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 63,430-participant average among 8 other Breast Cancer Screening trials with a reported enrollment target (100% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer Screening appearing as the primary indexed condition, and to 1 intervention - of which Breast Imaging is the first listed.

NCT07067788 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT07067788 about?

NCT07067788 is a clinical study titled "B.Brilliant Revelation Comparision Study". This is an observational study to evaluate the MAMMOMAT B.brilliant system. All diagnostic decisions are made by the treating radiologist based upon standard of care clinical imaging acquired on FDA approved devices

What is the current status of trial NCT07067788?

This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2025-12-15. Estimated completion is 2027-01-30.

What conditions does trial NCT07067788 study?

This clinical trial studies the following conditions: Breast Cancer Screening.

What interventions are being tested in trial NCT07067788?

The interventions under investigation include: Breast Imaging (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT07067788?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07067788 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer Screening

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.